Company / Cash & Equivalents
Incyte Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$3.1B
FY2025
5-year range
$1.7B / $3.2B
FY2021-FY2025
Trend
+83.5%
vs FY2024
Sector context
#11 of 207
Health Care
What the data says
Among 207 Health Care companies, Incyte is in the top 5% for cash & equivalents. Cash & Equivalents has fluctuated over the past 10 years, ranging from $652M in FY2016 to $3.2B in FY2023.
Based on SEC 10-K filings.
$3.1B in FY2025 with a 5-year CAGR of +15.4%. Top quartile in the Health Care sector.
Declined from $3.2B to $3.1B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +1.6%
- 5-Year CAGR
- +15.4%
- 10-Year CAGR
- -
Sector benchmark
Top 5% in Health CareTop 5% of 207This company $3.1B Sector average $669.5M
▼
+362.7% above sector average
Key checks
Key Insights
- 5-year CAGR of +15.4%, indicating consistent growth.
- In FY2025, cash & equivalents increased 83.5% year-over-year.
- Ranks #11 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.7%
- Strong return on equity: 25.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.1B | +83.5% |
| FY2024 | $1.7B | -47.5% |
| FY2023 | $3.2B | +8.9% |
| FY2022 | $3.0B | +43.5% |
| FY2021 | $2.1B | +36.0% |
| FY2020 | $1.5B | -17.4% |
| FY2019 | $1.8B | +57.4% |
| FY2018 | $1.2B | +29.4% |
| FY2017 | $899.5M | +37.9% |
| FY2016 | $652.3M | +25.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026